Form 4: United Therapeutics Director Christopher Causey Sells 510 Shares
SEC Form 4 Filing
Director Christopher Causey of United Therapeutics Corporation sold 510 shares of common stock on November 1, 2024, at a price of $376.6281 per share.
Summary
- On November 1, 2024, Christopher Causey, a director of United Therapeutics Corporation, sold 510 shares of the company's common stock.
- The sale price was $376.6281 per share.
- Following the transaction, Causey directly owns 3,675 shares of United Therapeutics Corporation.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a stock sale by a director. It doesn't inherently indicate positive or negative sentiment about the company's future.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders, such as directors and officers, trade their company's stock. These filings provide transparency into insider transactions, which can be closely watched by investors for signals about a company's prospects.
Stakeholder Impact
- Shareholders may interpret the director's stock sale in various ways, potentially affecting investor confidence.
Key Dates
| Date | Description |
|---|---|
| 11/01/2024 | Date of transaction: Christopher Causey sold 510 shares of United Therapeutics Corp. |
| 11/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.